Literature DB >> 8175925

Multiple mechanisms are responsible for altered expression of gap junction genes during oncogenesis in rat liver.

M J Neveu1, J R Hully, K L Babcock, E L Hertzberg, B J Nicholson, D L Paul, H C Pitot.   

Abstract

Although several abnormalities in gap junction (GJ) structure and/or function have been described in neoplasms, the molecular mechanisms responsible for many of the alterations remain unknown. The identification of a family of GJ proteins, termed connexins, prompted this study of connexin32 (Cx32), connexin26 (Cx26) and connexin43 (Cx43) expression during rat hepatocarcinogenesis. Using antibody, cDNA and cRNA probes, we investigated connexin mRNA and protein expression in preneoplastic and neoplastic rat livers. In normal liver, Cx32 is expressed in hepatocytes throughout the hepatic acinus, Cx26 is restricted to periportal hepatocytes, and Cx43 is expressed by mesothelial cells forming Glisson's capsule. Most preneoplastic altered hepatic foci generated by diethylnitrosamine (DEN) initiation and either phenobarbital (PB) or 2,3,7,8-dichlorodibenzo-p-dioxin (TCDD) promotion exhibited decreased Cx32 or increased Cx26 staining. Foci from either protocol failed to display Cx43 immunoreactivity. In the majority of PB-promoted foci, Cx32 immunoreactivity decreased independently of changes in mRNA abundance. Continuous thymidine labeling, following cessation of PB promotion, showed that downregulation of Cx32 staining is reversible in foci that are promoter-dependent for growth, but irreversible in lesions that are promoter-independent for growth. Hepatic neoplasms from rats initiated with DEN and promoted with PB or TCDD also displayed modified connexin expression. While all 24 neoplasms studied were deficient in normal punctate Cx32 and Cx26 staining, altered cellular localization of these proteins was apparent in some tumors. Immunoblotting of crude tissue extracts revealed that neoplasms with disordered Cx32 staining showed immunoreactive bands with altered electrophoretic mobility. These observations show that hepatomas may downregulate Cx32 expression through changes in the primary structure of Cx32 or by post-translational modifications. Northern blotting of total tumor mRNAs failed to demonstrate consistent changes in the abundance of Cx32, Cx26 or Cx43 transcripts. Some tumors expressed steady-state transcripts without observable immunoreactivity, indicating that some hepatomas downregulate connexin immunoreactivity independently of mRNA abundance. Increased levels of Cx43 mRNA and protein were found in several neoplasms, but immunostaining was always localized to nonparenchymal cells. Areas of bile duct proliferation and cholangiomas displayed Cx43 staining, whereas, cholangiocarcinomas were deficient in immunoreactivity. These findings show that alterations in the expression of connexins, by either downregulation or differential induction, represent common modifications during hepatocarcinogenesis. Although our results imply that connexins represent useful markers for the boundary between tumor promotion and progression, preneoplastic and neoplastic rat hepatocytes fail to use a common mechanism to modify connexin expression.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8175925     DOI: 10.1242/jcs.107.1.83

Source DB:  PubMed          Journal:  J Cell Sci        ISSN: 0021-9533            Impact factor:   5.285


  20 in total

1.  Different ionic selectivities for connexins 26 and 32 produce rectifying gap junction channels.

Authors:  T M Suchyna; J M Nitsche; M Chilton; A L Harris; R D Veenstra; B J Nicholson
Journal:  Biophys J       Date:  1999-12       Impact factor: 4.033

Review 2.  Roles of gap junctions and connexins in non-neoplastic pathological processes in which cell proliferation is involved.

Authors:  Maria Lúcia Zaidan Dagli; Francisco Javier Hernandez-Blazquez
Journal:  J Membr Biol       Date:  2007-07-25       Impact factor: 1.843

Review 3.  Liver repopulation and carcinogenesis: two sides of the same coin?

Authors:  Fabio Marongiu; Silvia Doratiotto; Stefania Montisci; Paolo Pani; Ezio Laconi
Journal:  Am J Pathol       Date:  2008-03-05       Impact factor: 4.307

4.  Transition from preinvasive carcinoma in situ to seminoma is accompanied by a reduction of connexin 43 expression in Sertoli cells and germ cells.

Authors:  Ralph Brehm; Christina Rüttinger; Petra Fischer; Isabella Gashaw; Elke Winterhager; Sabine Kliesch; Rainer M Bohle; Klaus Steger; Martin Bergmann
Journal:  Neoplasia       Date:  2006-06       Impact factor: 5.715

Review 5.  Zonation of metabolism and gene expression in liver.

Authors:  K Jungermann
Journal:  Histochem Cell Biol       Date:  1995-02       Impact factor: 4.304

6.  Expression of gap junction genes connexin 32, connexin 43 and their proteins in hepatocellular carcinoma and normal liver tissues.

Authors:  Xiang-Dong Ma; Yan-Fang Sui; Wen-Liang Wang
Journal:  World J Gastroenterol       Date:  2000-02       Impact factor: 5.742

7.  Signal transduction of gap junctional genes, connexin32, connexin43 in human hepatocarcinogenesis.

Authors:  Xiang-Dong Ma; Xing Ma; Yan-Fang Sui; Weng-Liang Wang; Chun-Mei Wang
Journal:  World J Gastroenterol       Date:  2003-05       Impact factor: 5.742

8.  Restoration of functional gap junctions through internal ribosome entry site-dependent synthesis of endogenous connexins in density-inhibited cancer cells.

Authors:  Hicham Lahlou; Marjorie Fanjul; Lucien Pradayrol; Christiane Susini; Stéphane Pyronnet
Journal:  Mol Cell Biol       Date:  2005-05       Impact factor: 4.272

9.  Expression of connexin 43 in normal canine testes and canine testicular tumors.

Authors:  Christina Rüttinger; Martin Bergmann; Ludger Fink; Sandra Pesch; Klaus Seitz; Astrid Trautmann; Klaus Steger; Lutz Konrad; Ralph Brehm
Journal:  Histochem Cell Biol       Date:  2008-04-30       Impact factor: 4.304

10.  Hepatic gap junctions in the hepatocarcinogen-resistant DRH rat.

Authors:  Takahiro Gotow; Motoko Shiozaki; Taneaki Higashi; Kentaro Yoshimura; Masahiro Shibata; Eiki Kominami; Yasuo Uchiyama
Journal:  Histochem Cell Biol       Date:  2008-07-17       Impact factor: 4.304

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.